Kevin R. Sayer - Jan 28, 2025 Form 4 Insider Report for DEXCOM INC (DXCM)

Role
Chairman, CEO & President, Director
Signature
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Kevin R. Sayer
Stock symbol
DXCM
Transactions as of
Jan 28, 2025
Transactions value $
-$2,899,367
Form type
4
Date filed
1/30/2025, 06:43 PM
Previous filing
Apr 10, 2024
Next filing
Mar 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DXCM Common Stock Award $0 +68.5K +24.13% $0.00 352K Jan 28, 2025 Direct F1, F2
transaction DXCM Common Stock Sale -$2.9M -33.4K -9.47% $86.91 319K Jan 29, 2025 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents performance stock units ("PSUs") granted to the reporting person on March 8, 2022 that vested on January 28, 2025.
F2 Included in this number are 109,641 unvested restricted stock units, 51,692 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 36,281 of which were granted on March 9, 2023 and shall vest through March 8, 2026, and 21,668 of which were granted on March 8, 2022 and shall vest through March 8, 2025.
F3 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.